Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians. 2021;:caac.21660.

Bai R, Chen N, Li L, Du N, Bai L, Lv Z, et al. Mechanisms of Cancer Resistance to Immunotherapy. Front Oncol. 2020;10:1290.

Article  PubMed  PubMed Central  Google Scholar 

Baghban R, Roshangar L, Jahanban-Esfahlan R, Seidi K, Ebrahimi-Kalan A, Jaymand M, et al. Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun Signal. 2020;18:59.

Article  PubMed  PubMed Central  Google Scholar 

Sarkar S, Horn G, Moulton K, Oza A, Byler S, Kokolus S, et al. Cancer Development, Progression, and Therapy: an epigenetic overview. IJMS. 2013;14:21087–113.

Article  PubMed  PubMed Central  Google Scholar 

Hanahan D. Hallmarks of Cancer: New dimensions. Cancer Discov. 2022;12:31–46.

Article  CAS  PubMed  Google Scholar 

Chew V, Toh HC, Abastado J-P. Immune Microenvironment in Tumor Progression: characteristics and challenges for Therapy. J Oncol. 2012;2012:1–10.

Article  Google Scholar 

Mao X, Xu J, Wang W, Liang C, Hua J, Liu J, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021;20:131.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Butti R, Kumar TVS, Nimma R, Banerjee P, Kundu IG, Kundu GC. Osteopontin Signaling in shaping Tumor Microenvironment Conducive to Malignant Progression. In: Birbrair A, editor. Tumor Microenvironment. Cham: Springer International Publishing; 2021. pp. 419–41.

Chapter  Google Scholar 

Andersson P, Yang Y, Hosaka K, Zhang Y, Fischer C, Braun H, et al. Molecular mechanisms of IL-33–mediated stromal interactions in cancer metastasis. JCI Insight. 2018;3:e122375.

Article  PubMed  PubMed Central  Google Scholar 

Butti R, Nimma R, Kundu G, Bulbule A, Kumar TVS, Gunasekaran VP, et al. Tumor-derived osteopontin drives the resident fibroblast to myofibroblast differentiation through Twist1 to promote breast cancer progression. Oncogene. 2021;40:2002–17.

Article  CAS  PubMed  Google Scholar 

Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018;32:1267–84.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sadeghalvad M, Mohammadi-Motlagh H-R, Rezaei N. Immune microenvironment in different molecular subtypes of ductal breast carcinoma. Breast Cancer Res Treat. 2021;185:261–79.

Article  CAS  PubMed  Google Scholar 

Del Gil CR, Huh SJ, Ekram MB, Trinh A, Liu LL, Beca F, et al. Immune escape in breast Cancer during in situ to Invasive Carcinoma Transition. Cancer Discov. 2017;7:1098–115.

Article  Google Scholar 

Salemme V, Centonze G, Cavallo F, Defilippi P, Conti L. The Crosstalk between Tumor Cells and the Immune Microenvironment in breast Cancer: implications for Immunotherapy. Front Oncol. 2021;11:610303.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 2004;4:540–50.

Article  CAS  PubMed  Google Scholar 

Debien V, De Caluwé A, Wang X, Piccart-Gebhart M, Tuohy VK, Romano E, et al. Immunotherapy in breast cancer: an overview of current strategies and perspectives. npj Breast Cancer. 2023;9:7.

Article  PubMed  PubMed Central  Google Scholar 

Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24:541–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garrido-Castro AC, Lin NU, Polyak K. Insights into Molecular classifications of Triple-negative breast Cancer: improving patient selection for treatment. Cancer Discov. 2019;9:176–98.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stark MC, Joubert AM, Visagie MH. Molecular Farming of Pembrolizumab and Nivolumab. IJMS. 2023;24:10045.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Krasniqi E, Barchiesi G, Pizzuti L, Mazzotta M, Venuti A, Maugeri-Saccà M, et al. Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives. J Hematol Oncol. 2019;12:111.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, et al. Pembrolizumab for early triple-negative breast Cancer. N Engl J Med. 2020;382:810–21.

Article  CAS  PubMed  Google Scholar 

Adel NG. Current treatment landscape and emerging therapies for metastatic triple-negative breast cancer. Am J Manag Care. 2021;27(Suppl 5):S87–96.

Article  PubMed  Google Scholar 

Franzoi MA, Romano E, Piccart M. Immunotherapy for early breast cancer: too soon, too superficial, or just right? Ann Oncol. 2021;32:323–36.

Article  CAS  PubMed  Google Scholar 

Dirix LY, Takacs I, Jerusalem G, Nikolinakos P, Arkenau H-T, Forero-Torres A, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN solid tumor study. Breast Cancer Res Treat. 2018;167:671–86.

Article  CAS  PubMed  Google Scholar 

Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Henriques B, Mendes F, Martins D. Immunotherapy in breast Cancer: when, how, and what challenges? Biomedicines. 2021;9:1687.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy. Blood. 2018;131:58–67.

Article  CAS  PubMed  Google Scholar 

Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016;39:98–106.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shimomura A, Fujiwara Y, Kondo S, Kodaira M, Iwasa S, Kitano S, et al. Tremelimumab-associated tumor regression following after initial progression: two case reports. Immunotherapy. 2016;8:9–15.

Article  CAS  PubMed  Google Scholar 

Tarhini A. CTLA-4 blockade: therapeutic potential in cancer treatments. OTT. 2010;3:15–25.

Loi S, Francis PA, Zdenkowski N, Gebski V, Fox SB, White M, et al. Neoadjuvant ipilimumab and nivolumab in combination with paclitaxel following anthracycline-based chemotherapy in patients with treatment resistant early-stage triple-negative breast cancer (TNBC): a single-arm phase 2 trial. JCO. 2022;40 16suppl:602–602.

Article  Google Scholar 

Santa-Maria CA, Kato T, Park J-H, Kiyotani K, Rademaker A, Shah AN, et al. A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer. Oncotarget. 2018;9:18985–96.

Article  PubMed  PubMed Central  Google Scholar 

Hwang WL, Pike LRG, Royce TJ, Mahal BA, Loeffler JS. Safety of combining radiotherapy with immune-checkpoint inhibition. Nat Rev Clin Oncol. 2018;15:477–94.

Article  PubMed  Google Scholar 

Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, et al. Incidence of endocrine dysfunction following the use of different Immune checkpoint inhibitor regimens: a systematic review and Meta-analysis. JAMA Oncol. 2018;4:173.

Article  PubMed  Google Scholar 

Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of Chemotherapy plus a monoclonal antibody against HER2 for metastatic breast Cancer that overexpresses HER2. N Engl J Med. 2001;344:783–92.

Article  CAS  PubMed  Google Scholar 

Muntasell A, Cabo M, Servitja S, Tusquets I, Martínez-García M, Rovira A, et al. Interplay between natural killer cells and Anti-HER2 antibodies: perspectives for breast Cancer immunotherapy. Front Immunol. 2017;8:1544.

Article  PubMed  PubMed Central  Google Scholar 

Early Breast Cancer Trialists’ Collaborative group (EBCTCG). Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. Lancet Oncol. 2021;22:1139–50.

Article  Google Scholar 

Kreutzfeldt J, Rozeboom B, Dey N, De P. The trastuzumab era: current and upcoming targeted HER2 + breast cancer therapies. Am J Cancer Res. 2020;10:1045–67.

PubMed  PubMed Central  Google Scholar 

García-Aranda M, Redondo M, Immunotherapy. A challenge of breast Cancer Treatment. Cancers. 2019;11:1822.

Article